harbor EML4-ALK. J Clin Oncol 27
(26):4247–4253. https://doi.org/10.1200/
JCO.2009.22.6993
- Inamura K, Takeuchi K, Togashi Y, Hatano S,
Ninomiya H, Motoi N, Mun MY, Sakao Y,
Okumura S, Nakagawa K, Soda M, Choi YL,
Mano H, Ishikawa Y, Nakagawa K (2009)
EML4-ALK lung cancers are characterized by
rare other mutations, a TTF-1 cell lineage, an
acinar histology, and young onset. Mod Pathol
22(4):508–515. https://doi.org/10.1038/
modpathol.2009.2
- Soda M, Takada S, Takeuchi K, Choi YL,
Enomoto M, Ueno T, Haruta H, Hamada T,
Yamashita Y, Ishikawa Y, Sugiyama Y, Mano H
(2008) A mouse model for EML4-ALK-posi-
tive lung cancer. Proc Natl Acad Sci 105
(50):19893–19897. https://doi.org/10.
1073/pnas.0805381105
- Kim DW, Mehra R, Tan DS, Felip E, Chow
LQ, Camidge DR, Vansteenkiste J, Sharma S,
De Pas T, Riely GJ, Solomon BJ, Wolf J,
Thomas M, Schuler M, Liu G, Santoro A,
Sutradhar S, Li S, Szczudlo T, Yovine A, Shaw
AT (2016) Activity and safety of ceritinib in
patients with ALK-rearranged non-small-cell
lung cancer (ASCEND-1): updated results
from the multicentre, open-label, phase
1 trial. Lancet Oncol 17(4):452–463.https://
doi.org/10.1016/S1470-2045(15)00614-2
- Ou SH, Ahn JS, De Petris L, Govindan R, Yang
JC, Hughes B, Lena H, Moro-Sibilot D,
Bearz A, Ramirez SV, Mekhail T, Spira A,
Bordogna W, Balas B, Morcos PN, Monnet A,
Zeaiter A, Kim DW (2015) Alectinib in
crizotinib-refractory ALK-rearranged non–-
small-cell lung cancer: a phase II global study.
J Clin Oncol 34(7):661–668.https://doi.org/
10.1200/JCO.2015.63.9443.
- Shaw AT, Gandhi L, Gadgeel S, Riely GJ,
Cetnar J, West H, Camidge DR, Socinski MA,
Chiappori A, Mekhail T, Chao BH,
Borghaei H, Gold KA, Zeaiter A,
Bordogna W, Balas B, Puig O, Henschel V,
Ou SH (2016) Alectinib in ALK-positive, cri-
zotinib-resistant, non-small-cell lung cancer: a
single-group, multicentre, phase 2 trial. Lancet
Oncol 17(2):234–242. https://doi.org/10.
1016/S1470-2045(15)00488-X
71. Shaw AT, Kim DW, Mehra R, Tan DS, Felip E,
Chow LQ, Camidge DR, Vansteenkiste J,
Sharma S, De Pas T, Riely GJ, Solomon BJ,
Wolf J, Thomas M, Schuler M, Liu G,
Santoro A, Lau YY, Goldwasser M, Boral AL,
Engelman JA (2014) Ceritinib in
ALK-rearranged non–small-cell lung cancer.
N Engl J Med 370(13):1189–1197.https://
doi.org/10.1056/NEJMoa1311107.
72. Shaw AT, Kim DW, Nakagawa K, Seto T,
Crino ́L, Ahn MJ, De Pas T, Besse B, Solomon
BJ, Blackhall F, Wu YL, Thomas M, O’Byrne
KJ, Moro-Sibilot D, Camidge DR, Mok T,
Hirsh V, Riely GJ, Iyer S, Tassell V, Polli A,
Wilner KD, J€anne PA (2013) Crizotinib versus
chemotherapy in advanced ALK-positive lung
cancer. N Engl J Med 368(25):2385–2394.
https://doi.org/10.1056/NEJMoa1214886
73. Solomon BJ, Mok T, Kim DW, Wu YL,
Nakagawa K, Mekhail T, Felip E,
Cappuzzo F, Paolini J, Usari T, Iyer S,
Reisman A, Wilner KD, Tursi J, Blackhall F,
PROFILE 1014 Investigators (2014) First-
line crizotinib versus chemotherapy in
ALK-positive lung cancer. N Engl J Med 371
(23):2167–2177. https://doi.org/10.1056/
NEJMoa1408440
74. Zou HY, Li Q, Lee JH, Arango ME, McDon-
nell SR, Yamazaki S, Koudriakova TB, Alton G,
Cui JJ, Kung PP, Nambu MD, Los G, Bender
SL, Mroczkowski B, Christensen JG (2007) An
orally available small-molecule inhibitor of
c-met, PF-2341066, exhibits cytoreductive
antitumor efficacy through antiproliferative
and antiangiogenic mechanisms. Cancer Res
67(9):4408–4417.https://doi.org/10.1158/
0008-5472.CAN-06-4443
75. Gettinger SN, Bazhenova LA, Langer CJ,
Salgia R, Gold KA, Rosell R, Shaw AT, Weiss
GJ, Tugnait M, Narasimhan NI, Dorer DJ,
Kerstein D, Rivera VM, Clackson T, Haluska
FG, Camidge DR (2016) Activity and safety of
brigatinib in ALK-rearranged non-small-cell
lung cancer and other malignancies: a single-
arm, open-label, phase 1/2 trial. Lancet Oncol
17(12):1683–1696. https://doi.org/10.
1016/S1470-2045(16)30392-8
The Introduction and Clinical Application of Cell-Free Tumor DNA 65
